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CURRENTLY there is considerable
interest in the application of immuno-
therapy employing agents such as Bacillus
Calmette-Guerin (B.C.G.) to the treat-
ment of human malignant disease. Thus,
skin scarification of B.C.G., together with
injections of irradiated leuLkaemic cells,
prolongs chemotherapeutically induced
remissions in acute lymphocytic (Mathe
et al., 1969a, 1973) and mycloblastic
(Powles et al., 1973) leukaemia and in-
jections of viable leukaemic cells in
admixture with B.C.G. substantially pro-
long survival in patients with chronic
myelocytic leukaemia (Sokal, Aungst and
Grace, 1973). Repeated skin scarification
of B.C.G. also prolongs survival of pa-
tients following surgical removal of melan-
oma (Gutterman et al., 1973; Bluming et
al., 1972). In addition, intralesional in-
jections of B.C.G. restrict growth of
surface melanomata (Morton et al., 1970;
Bornstein et al., 1973; Pinsky, Hirshaut
and Oettgen, 1973) and the feasibility
of using intravenously injected B.C.G. in
treatment of myeloblastic leukaemia has
been indicated (Whittaker et al., 1973).
B.C.G. vaccine is, however, a potentially
toxic material and adverse effects, in-
cluding generalized B.C.G. infection and
hepatic dysfunction associated with liver
granuloma formation, have been observed
in patients receiving skin scarification and
intralesional injections of B.C.G., or in-
jections of tumour cells in admixture with
the vaccine (Sparks et al., 1973; Pinsky et
al., 1973; Hunt et al., 1973). Recently,
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however, it has been reported that
administration ofB.C.G. orally to patients
with malignant melanoma produced bene-
ficial effects in a few cases (Falk, Mann
and Langer, 1973). Orally administered
B.C.G. is relatively non-toxic, more than
200 mg of vaccine being well tolerated
clinically in immunization against tuber-
culosis (Leading article, 'ubercle, 1960).
Particularly in view of the low toxicity
and ease of administration, the tumour
suppressive properties of B.C.G. given
orally require experimental examination.
The present studies were carried out to
assess the influence of orally administered
vaccine on intraperitoneal, pulmonary
and metastatic growth of transplanted
rat tumours.
MATERIALS AND METHODS
Tumours.-The tumours used were in-
duced or arose spontaneously in rats of an
inbred Wistar strain and maintained by sub-
cutaneous transplantation in rats ofthe same
sex as the primary donor. Sarcoma Mc57
was induced by subcutaneous implantation of
3-methyleholanthrene. Epithelioma Spi
arose spontaneously and regularly produced
pulmonary metastases from subcutaneous
grafts, even following their surgical removal
(Baldwin, 1966; Baldwin and Pimm, 1973a).
Single cell suspensions were prepared by
digestion of finely minced tissue in 0-25%o trypsin in Hanks' balanced salt solution and
resuspension in medium 199.
B.C.G.-Freeze-dried B.C.G. vaccine (Per-
cutaneous) w%Aas supplied by Glaxo ResearchINFLUENCE OF ORALLY ADMINISTERED B.C.G. ON RAT TUMOURS
Ltd, Greenford, Middlesex. The vaccine xvas
reconstituted in water to 10 mg moist weight
of organisms/ml.
Methods of treatment.-Rats receiving
challenge inocula of sarcoma Mc57 intra-
peritoneally or intravenously were treated by
single or repeated intraoesophageal gastric
instillation of B.C.G. (0 2-6 0 mg moist
weight). With the epithelioma Spl, rats
were treated by repeated oral administration
of B.C.G. follow%ing surgical removal of 9-day
old subcutaneous growths, measuring 1-2 cm
mean diameter.
Assessmient of tumour growvth. When sar-
coma Mc57 cells were injected intraperiton-
eally tumourn masses M-ere removed and
weighed at termination of the experiments.
In tests where animnals developed pulmonary
tumour deposits from intravenously injected
sarcoma Mc57 cells, or by spontaneous
metastases from epithelioma Spl, they were
killed individually when showing respiratory
distress and survivals calculated with respect,
to the day of tumour cell injection. Pul-
monary growth was demonstrated by per-
fusion of lungs w,ith dilute India ink (Wexler,
1966) and the number ofmacroscopic nodules
on the lung surface counted.
RESULTS
In 2 tests witlh the sarcoma Mca57,
where ttumour cells (1 x 106) were injected
intraperitoneally (Table I), daily adminis-
tration of 0-5 mg moist weight of B.C.G.
throughout the entire course of the
experiments (total dose 8X5 mg) was
without influence on intraperitoneal tu-
mour growth. In the first experiment,
which was terminated after 17 days, all
treated rats had multiple intraperitoneal
masses with mean tumour weights of
16-3 g, comparable with those in control
rats (mean 16 8 g). A similar result
was obtained in the second test, both
control and treated rats developing com-
parable intraperitoneal tumours.
Table II shows the results of tests
to assess the effect of orally administered
B.C.G. on the pulmonary growth of
intravenously injected cells of sarcoma
Mc57. In the first experiment, 2 x 106
sarcoma Mc57 cells were injected intra-
venously and animals treated with a
single oral administration of 6 mg moist
weight of B.C.G. Control rats survived
for 19-21 days (mean 20-6 days) and all
developed in excess of 200 pulmonarv
tumour deposits, while treated rats sur-
vived for 20-21 days (mean 20 8 days)
and all of these also had 200+ lung
tumour nodules. In 3 similar tests (Ex-
periments 2, 3 and 4) with intravenous
inocula of 5 x l05-2 x 106 sarcoma Mc57
cells, animals were treated daily with
B.C.G. until they had to be killed because
of respiratory distress caused by pul-
monary tumour growth. However, in no
case did treatment prolong survival or
reduce the numbers of tumour deposits
in the lungs, even when animals were
treated with 3 0 mg moist weight of
B.C.G. daily for up to 24 days (total
dose up to 72 mg/rat).
The final test was carried out with
the epithelioma Spl. Nine-day old sub-
cutaneous grafts were surgically removed
and animals then treated daily with
1 0 mg moist weight of B.C.G. until they
had to be killed due to development of
spontaneous pulmonary metastases. All
(4/4) control rats survived for 28 davs
and had macroscopically visible meta-
stases (1, 27, 180, 200+ nodules/lung).
Treated rats had to be killed after 26-28
TABLE I. Influence of Orally Administered B.C(.G. on Intraperitoneal Growth of
Sarcoma Mc57
No. of cells
Expt injected
I 1 X 106
1 X 106
2 1 X 1(6
1 X 1(0)6
Daily dose B.C.G.
(mg moist
weight)
0 5
Experiment No. of rats
teirmiinate(d with peiritoneal
((lay*) tumours
17 5/5
17 5/5
17 5/5
17 5/5
* With respect to tumour cell injectioni.
AMeani weight
of tumours
(g)
16 *3
16-8
17 -6
18 2
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TABLE II.-Influence of Orally Administered B.C.G. on Pulmonary Growth of
Sarcoma Mc57
No. of cells
Oral dose B.C.G.
A<
injected mg moist Survival
;xpt intravenously weight Day* (days)
1 2 x 106 6-0 0 20, 21, 21, 21, 21
(Mean 20*8)
2 x 106 - 19, 21, 21, 21, 21
(Mean 20 -6)
2 5 x 105 0 5 Daily 26, 26, 29, 35, 35
(Mean 30 2)
5 x 105 - - 26,26,38,38
(Mean 32 0)
3 1 x 106 0-2 Daily 14, 15, 15, 15, 15
(Mean 14-8)
1 x 106 - - 15, 15, 15, 15, 15
(Mean 15-0)
4 2 x 106 3 0 Daily 18, 21, 21, 24, 24
(Mean 21
-6)
2 x 106 - - 19, 21, 21, 25, 25
(Mean 22 -2)
* With respect to tumour cell injection.
days and all of these (5/5) also had
pulmonary metastases (55, 90, 180, 200+,
200+ nodules/lung).
DISCUSSION
These studies establish that orally
administered B.C.G. vaccine does not
influence intraperitoneal or pulmonary
growth of a transplanted rat sarcoma or
restrict the development of post-surgical
pulmonary metastases from a trans-
planted epithelioma.
The lack of effectiveness of com-
paratively large doses of B.C.G. ad-
ministered orally contrasts markedly with
the ability of the vaccine to suppress
growth of tumours described in this
paper when the vaccine is introduced
directly into the environment of tumour
growth. Thus, in the present studies
daily oral administration of 0 5 mg of
B.C.G. did not restrict intraperitoneal
development of sarcoma Mc57, although
a single injection of 100 ,ug of the vaccine
directly into the peritoneal cavity com-
pletely suppresses tumour growth at this
site (Pimm, 1974). Also in contrast to
the present findings, pulmonary tumour
growth of sarcoma cells is completely
abolished following the introduction of
B.C.G. into pulmonary tissue by a single
intravenous injection ofthe vaccine (Bald-
win and Pimm, 1973c). In addition,
post-surgical pulmonary metastases of
epithelioma Spl can be significantly re-
duced by repeated intravenous adminis-
tration of B.C.G. (Baldwin and Pimm,
1973a).
While general immunostimulation by
nonspecific agents such as B.C.G. may be
tumour suppressive in a number of
experimental situations (Mathe, Pouillart
and Lapeyraque, 1969b; Parr, 1972;
Currie and Bagshawe, 1970; Woodruff and
Boak, 1966), many other recent studies
have emphasized that direct contact
between B.C.G. organisms and tumour
cells produces a more marked suppression
oftumourgrowth. Thus, syngeneic trans-
plants of several tumours, including di-
ethylnitrosamine induced guinea-pig hepa-
tomata (Zbar, Bernstein and Rapp, 1971)
and 3-methylcholanthrene induced rat
and mouse sarcomata (Baldwin and Pimm,
1971, 1973b; Bartlett, Zbar and Rapp,
1972) are suppressed when cells are
injected locally in admixture with B.C.G.,
and intralesional injection of B.C.G. may
retard growth of transplanted sarcomata
F
No. of rats
with lung
tumours
5/5
5/5
5/5
4/4
5/5
5/5
5/5
5/5
No.
nodules/lung
5 x 200 +
5 x 200 +
5 x 200 +
4 x 200 +
5 x 200 +
5 x 200 +
50, 56, 103,
140, 200 +
59, 92,
3 X 200 +
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(Baldwin and Pimm, 1971), hepatomata
(Zbar et al., 1972a) and primary mouse
mammary carcinomata (Simmons, Rios
and Kersey, 1972). In addition, mixed
inocula of tumour cells and B.C.G.
organisms may be used for active immuno-
therapy of subcutaneous and pulmonary
tumour deposits (Baldwin and Pimm,
1973b, c).
The present findings do not rule out
the possibility that a general immuno-
stimulation may be produced by orally
administered B.C.G. and this may have
some beneficial clinical effects (Falk et
al., 1973). However, the indication is
that in those situations where marked
tumour suppression can be achieved by
contact between tumour cells and B.C.G.
this effect may be lost by administering
B.C.G. orally, even in comparatively
massive doses. It might, therefore, be
unwise in those clinical situations where
treatment by contact between malignant
tissue and B.C.G. organisms is established
to be suppressive, such as in melanoma,
or where injections of B.C.G. and in-
activated malignant cells are being used
for active immunotherapy, to attempt to
minimize toxic effects of B.C.G. by
administering the vaccine orally. Ad-
verse effects may perhaps be better
eliminated by the use of non-living
B.C.G. organisms or mycobacterial sub-
cellular fractions. For instance, intact
B.C.G. organisms sterilized by y irradia-
tion (Baldwin et al., 1974) and myco-
bacterial methanol extraction residue
(Weiss and Wells, 1960) retain tumour
suppressive properties when contacted
with malignant cells (Baldwin and Hop-
per, unpublished findings), and B.C.G.
cell wall fragments attached to oil droplet
emulsions inhibit local tumour growth
(Zbar, Rapp aind Ribi, 1972b) and pul-
monary metastases (Baldwin and Pimm,
1973d).
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